Cerebral Palsy (CP) Syndromes
Cerebral palsy refers to nonprogressive syndromes characterized by impaired voluntary movement or posture and resulting from prenatal developmental malformations or perinatal or postnatal CNS damage. Syndromes manifest before age 2 yr. Diagnosis is clinical. Treatment may include physical and occupational therapy, braces, drug therapy or botulinum toxin injections, orthopedic surgery, intrathecal baclofen, or, in certain cases, dorsal rhizotomy.
Cerebral palsy (CP) is a group of syndromes that causes nonprogressive spasticity, ataxia, or involuntary movements; it is not a specific disorder or single syndrome. CP syndromes occur in 0.1 to 0.2% of children and affect up to 15% of premature infants.
Etiology is multifactorial, and a specific cause is sometimes hard to establish. Prematurity, in utero disorders, neonatal encephalopathy, and kernicterus often contribute. Perinatal factors (eg, perinatal asphyxia, stroke, CNS infections) probably cause 15 to 20% of cases.
Examples of types of CP are
CNS trauma or a severe systemic disorder (eg, stroke, meningitis, sepsis, dehydration) during early childhood (before age 2 yr) may also cause a CP syndrome.
Before a specific syndrome develops, symptoms include lagging motor development and often persistent infantile reflex patterns, hyperreflexia, and altered muscle tone.
Syndromes are categorized mainly as one of the following, depending on which parts of the CNS are malformed or damaged:
Spastic syndromes occur in > 70% of cases. Spasticity is a state of resistance to passive range of motion; resistance increases with increasing speed of that motion. It is due to upper motor neuron involvement and may mildly or severely affect motor function. These syndromes may cause hemiplegia, quadriplegia, diplegia, or paraplegia. Usually, deep tendon reflexes in affected limbs are increased, muscles are hypertonic, and voluntary movements are weak and poorly coordinated. Joint contractures develop, and joints may become misaligned. A scissors gait and toe walking are typical. In mild cases, impairment may occur only during certain activities (eg, running). Corticobulbar impairment of oral, lingual, and palatal movement, with consequent dysarthria or dysphagia, commonly occurs with quadriplegia.
Athetoid or dyskinetic syndromes occur in about 20% of cases and result from basal ganglia involvement. The syndromes are defined by slow, writhing, involuntary movements of the proximal extremities and trunk (athetoid movements), often activated by attempts at voluntary movement or by excitement. Abrupt, jerky, distal (choreic) movements may also occur. Movements increase with emotional tension and disappear during sleep. Dysarthria occurs and is often severe.
Ataxic syndromes occur in < 5% of cases and result from involvement of the cerebellum or its pathways. Weakness, incoordination, and intention tremor cause unsteadiness, a wide-based gait, and difficulty with rapid or fine movements.
Mixed syndromes are common—most often with spasticity and athetosis.
About 25% of patients, most often those with spasticity, have other manifestations. Strabismus and other visual defects may occur. Children with athetosis due to kernicterus commonly have nerve deafness and upward gaze paralysis.
Many children with spastic hemiplegia or paraplegia have normal intelligence; children with spastic quadriplegia or a mixed syndrome may have severe intellectual disability.
If CP is suspected, identifying the underlying disorder is important. History may suggest a cause. A cranial MRI is done; it can detect abnormalities in most cases.
CP can rarely be confirmed during early infancy, and the specific syndrome often cannot be characterized until age 2 yr. High-risk children (eg, those with evidence of asphyxia, stroke, periventricular abnormalities seen on cranial ultrasonography in premature infants, jaundice, meningitis, neonatal seizures, hypertonia, hypotonia, or reflex suppression) should be followed closely.
CP should be differentiated from progressive hereditary neurologic disorders and disorders requiring surgical or other specific neurologic treatments.
Ataxic forms are particularly hard to distinguish, and in many children with persistent ataxia, a progressive cerebellar degenerative disorder is ultimately identified as the cause.
Athetosis, self-mutilation, and hyperuricemia in boys indicate Lesch-Nyhan syndrome.
Cutaneous or ocular abnormalities may indicate tuberous sclerosis, neurofibromatosis, ataxia-telangiectasia, von Hippel–Lindau disease, or Sturge-Weber syndrome.
Infantile spinal muscular atrophy, muscular dystrophies, and neuromuscular junction disorders associated with hypotonia and hyporeflexia usually lack signs of cerebral disease.
Adrenoleukodystrophy begins later in childhood, but other leukodystrophies begin earlier and may be mistaken for CP at first.
When history and/or cranial MRI does not clearly identify a cause, laboratory tests should be done to exclude certain progressive storage disorders that involve the motor system (eg, Tay-Sachs disease, metachromatic leukodystrophy, mucopolysaccharidoses) and metabolic disorders (eg, organic or amino acid metabolism disorders).
Other progressive disorders (eg, infantile neuroaxonal dystrophy) may be suggested by nerve conduction studies and electromyography. These and many other brain disorders that cause CP (and other manifestations) are being increasingly identified with genetic testing, which may be done to check for a specific disorder or to screen for many disorders (microarray and whole genome testing).
Most children survive to adulthood. Severe limitations in sucking and swallowing, which may require feeding by gastrostomy tube, decrease life expectancy.
The goal is for children to develop maximal independence within the limits of their motor and associated deficits. With appropriate management, many children, especially those with spastic paraplegia or hemiplegia, can lead near-normal lives.
Physical therapy and occupational therapy for stretching, strengthening, and facilitating good movement patterns are usually used first and are continued. Bracing, constraint therapy, and drugs may be added.
Botulinum toxin may be injected into muscles to decrease their uneven pull at joints and to prevent fixed contractures.
Baclofen, benzodiazepines (eg, diazepam), tizanidine, and sometimes dantrolene may diminish spasticity. Intrathecal baclofen (via subcutaneous pump and catheter) is the most effective treatment for severe spasticity.
Orthopedic surgery (eg, muscle-tendon release or transfer) may help reduce restricted joint motion or misalignment. Selective dorsal rhizotomy, done by neurosurgeons, may help a few children if spasticity affects primarily the legs and if cognitive abilities are good.
When intellectual limitations are not severe, children may attend mainstream classes and take part in adapted exercise programs and even competition. Speech training or other forms of facilitated communication may be needed to enhance interactions.
Some severely affected children can benefit from training in activities of daily living (eg, washing, dressing, feeding), which increases their independence and self-esteem and greatly reduces the burden for family members or other caregivers. Assistive devices may increase mobility and communication, help maintain range of motion, and help with activities of daily living. Some children require varying degrees of lifelong supervision and assistance.
Many children's facilities are establishing transition programs for patients as they become adults and have fewer supports to help with special needs.
Parents of a child with chronic limitations need assistance and guidance in understanding the child’s status and potential and in dealing with their own feelings of guilt, anger, denial, and sadness (see Children with Chronic Health Conditions : Effects on the family). These children reach their maximal potential only with stable, sensible parental care and the assistance of public and private agencies (eg, community health agencies, vocational rehabilitation organizations, lay health organizations such as the United Cerebral Palsy Association—see UCP.org).
Cerebral palsy is a syndrome (not a specific disorder) that involves nonprogressive spasticity, ataxia, and/or involuntary movements.
Etiology is often multifactorial and sometimes unclear but involves prenatal and perinatal factors that are associated with CNS malformation or damage (eg, genetic and in utero disorders, prematurity, kernicterus, perinatal asphyxia, stroke, CNS infections).
Intellectual disability and other neurologic manifestations (eg, strabismus, deafness) are not part of the syndrome but may be present depending on the cause.
Syndromes manifest before age 2 yr; later onset of similar symptoms suggests another neurologic disorder.
Do cranial MRI and, if needed, testing for hereditary metabolic and neurologic disorders.
Treatment depends on the nature and degree of disability, but physical therapy and occupational therapy are typically used; some children benefit from bracing, botulinum toxin, benzodiazepines, other muscle relaxants, intrathecal baclofen, and/or surgery (eg, muscle-tendon release or transfer, rarely dorsal rhizotomy).
Drug NameSelect Trade